Mr. Waseem Ali : Leading Researcher in Drug Repurposing
PhD Student at Drug Repurposing, Guru Nanak Dev Engineering College, Ludhiana, Punjab, India
He remarkable academic journey, extensive research contributions, and dedication to the field of psychology are truly commendable. Your wealth of knowledge and diverse skill set reflect a deep commitment to understanding and addressing critical issues such as bullying, inclusion, and socialization.
🔬 He successful completion of a PhD in Psychology, along with the numerous advanced courses and workshops, showcases your continuous pursuit of excellence and expertise in your field.
🏆 The awards and recognitions, including the First Place in the Poster Award at the University of Stavanger, underscore the impact of your research and the high regard it holds in the academic community.
Professional Profiles:
Education:
Mr. Waseem Ali achieved academic success throughout his educational journey. In 2011, he secured a First Division in the Matriculation examination from the C.B.S.E. Board, India, with a focus on Science. Continuing his impressive performance, he obtained a Second Division in the Higher Secondary examination in 2013 from the same board. In 2016, he graduated with a Second Division from C.C.S. University, Meerut, specializing in Biotechnology with a focus on molecular biology. His commitment to excellence was further demonstrated in 2018 when he completed his Post Graduation with a First Division from Jamia Hamdard, New Delhi, specializing in Biotechnology with a focus on molecular biology.
Experience:
Mr. Waseem Ali has held several positions in the field of Biotechnology and molecular biology. From 05-08-2022 to 29-12-2022, he served as a Project Assistant at Jamia Hamdard, where he contributed to a project aiming to decipher novel targets of M.tb pathogenesis that manipulate host defenses in compromised hosts. The identified targets may be utilized to develop anti-TB agents effective against drug-resistant isolates. His supervisor during this time was Dr. Javaid A Shaikh. Prior to this, from 15-01-2019 to 04-08-2022, Mr. Ali worked as a Project Assistant at Jamia Hamdard, focusing on determining the effect of FDA-approved drugs against M.tb. He evaluated the efficacy of selected drugs against M.tb in vitro and ex vivo, using molecular docking, simulation, and biophysical methods to predict their binding affinity and effect with target proteins. His supervisors during this period were Prof. S. E. Hasnain and Dr. Sonam Grover. Currently, since 04-01-2021, Mr. Ali is pursuing his Ph.D. at Jamia Hamdard under the guidance of Prof. S. E. Hasnain and Dr. Sonam Grover, focusing on research related to drug repurposing.
Publications:
Mr. Waseem Ali has co-authored several research papers in reputable journals. In “Microbes and Infection” in 2023, he collaborated with Salma Jamal, Rishabh Gangwar, Faraz Ahmed, Isha Pahuja, Rahul Sharma, Ved Prakash Dwivedi, Meetu Agarwa, and Sonam Grover on a paper titled “Unravelling the potential of Triflusal as an anti-TB repurposed drug by targeting replication protein DciA,” which was published on 5.8. In “Molecular Informatics” in 2023, he worked with Salma Jamal, Rishabh Gangwar, Faraz Ahmed, Rahul Sharma, Meetu Agarwal, Javaid Ahmad Sheikh, Abhinav Grover, and Sonam Grover on a paper titled “Targeting of essential mycobacterial replication enzyme DnaG primase revealed Mitoxantrone and Vapreotide as novel mycobacterial growth inhibitors,” which was published on 4.05. Additionally, in “Computational and Structural Biotechnology Journal” in 2021, he contributed to a paper titled “Computational modeling and bioinformatic analyses of functional mutations in drug target genes in Mycobacterium tuberculosis,” co-authored with Pooja Singh, Salma Jamal, Faraz Ahmed, Najumu Saqib, Seema Mehra, Deodutta Roy, Nasreen Z Ehtesham, and Seyed E Hasnain. In “Journal of Translational Medicine” in 2021, Mr. Ali collaborated with Salma Jamal, Priya Nagpal, Abhinav Grover, and Sonam Grover on a paper titled “Computational models for the prediction of adverse cardiovascular drug reactions,” which was published on 8.44.